The detailed in vivo clinical study
 A randomized, double-blind, placebo-controlled trial was conducted on 1961 overweight or obese adults (without diabetes).
 Participants received 2.4 mg of semaglutide (GLP-1) subcutaneously every week for 68 weeks , along with standardized lifestyle and dietary advice.
The Maya Slim® Appetite Suppressant Patches formula is inspired by these scientifically validated mechanisms, transmitting a dosage and synergy of active ingredients that promote the natural control of satiety.
 
   
      
     
       
 
 
 
 
 
 
 
 
 
       
       
       
       
       
       
       
 
      